Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C30H38ClN7O3 |
Molecular Weight | 580.121 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=O)C1=C(NC2=NC(NC3=CC=C4C[C@H](CCCC4=C3OC)N5CCN(CCO)CC5)=NC=C2Cl)C=CC=C1
InChI
InChIKey=BCSHRERPHLTPEE-NRFANRHFSA-N
InChI=1S/C30H38ClN7O3/c1-32-29(40)23-7-3-4-9-25(23)34-28-24(31)19-33-30(36-28)35-26-11-10-20-18-21(6-5-8-22(20)27(26)41-2)38-14-12-37(13-15-38)16-17-39/h3-4,7,9-11,19,21,39H,5-6,8,12-18H2,1-2H3,(H,32,40)(H2,33,34,35,36)/t21-/m0/s1
Molecular Formula | C30H38ClN7O3 |
Molecular Weight | 580.121 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/27527804Curator's Comment: Description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/27009091 |
https://www.ncbi.nlm.nih.gov/pubmed/26753004
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27527804
Curator's Comment: Description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/27009091 |
https://www.ncbi.nlm.nih.gov/pubmed/26753004
CEP-37440 is a potent ATP-competitive, highly kinase selective, and orally active inhibitor of FAK1 and anaplastic lymphoma kinase (ALK). In addition to a favorable metabolic stability and pharmacokinetic profile preclinically, CEP-37440 is also a brain penetrant. CEP-37440 was able to inhibit the proliferation of certain IBC cells by decreasing the levels of phospho-FAK1 (Tyr 397); none of the cells expressed ALK. Studies using IBC xenograft models showed that CEP-37440 also effectively reduces the growth of the primary tumor xenografts and inhibits the development of brain metastases in mice.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2695 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27527804 |
2.0 nM [IC50] | ||
Target ID: CHEMBL4247 |
3.1 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1533 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27527804 |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CEP-37440 plasma | Mus musculus population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1612 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27527804 |
1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
CEP-37440 plasma | Mus musculus population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
16429 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27527804 |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CEP-37440 plasma | Mus musculus population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27527804 |
1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
CEP-37440 plasma | Mus musculus population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01922752
CEP-37440 supplied as 25 mg and 100 mg capsules and orally administered daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27527804
CEP-37440 was screened against both NPM-ALK+ ALCL cell lines (Sup-M2 and Karpas-299) and NPM-ALK− hematologic cell lines (Hut-102 and K562) and demonstrated selective cytotoxicity in the oncogene-addicted cell lines in nanomolar range
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:50:13 GMT 2023
by
admin
on
Sat Dec 16 05:50:13 GMT 2023
|
Record UNII |
O3MNS8782H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 05:50:13 GMT 2023 , Edited by admin on Sat Dec 16 05:50:13 GMT 2023
|
||
|
NCI_THESAURUS |
C141136
Created by
admin on Sat Dec 16 05:50:13 GMT 2023 , Edited by admin on Sat Dec 16 05:50:13 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1609103-92-5
Created by
admin on Sat Dec 16 05:50:13 GMT 2023 , Edited by admin on Sat Dec 16 05:50:13 GMT 2023
|
NO STRUCTURE GIVEN | |||
|
71721648
Created by
admin on Sat Dec 16 05:50:13 GMT 2023 , Edited by admin on Sat Dec 16 05:50:13 GMT 2023
|
PRIMARY | |||
|
C111685
Created by
admin on Sat Dec 16 05:50:13 GMT 2023 , Edited by admin on Sat Dec 16 05:50:13 GMT 2023
|
PRIMARY | |||
|
1391712-60-9
Created by
admin on Sat Dec 16 05:50:13 GMT 2023 , Edited by admin on Sat Dec 16 05:50:13 GMT 2023
|
PRIMARY | |||
|
DB13060
Created by
admin on Sat Dec 16 05:50:13 GMT 2023 , Edited by admin on Sat Dec 16 05:50:13 GMT 2023
|
PRIMARY | |||
|
DTXSID301025939
Created by
admin on Sat Dec 16 05:50:13 GMT 2023 , Edited by admin on Sat Dec 16 05:50:13 GMT 2023
|
PRIMARY | |||
|
O3MNS8782H
Created by
admin on Sat Dec 16 05:50:13 GMT 2023 , Edited by admin on Sat Dec 16 05:50:13 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545051
Created by
admin on Sat Dec 16 05:50:13 GMT 2023 , Edited by admin on Sat Dec 16 05:50:13 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
INHIBITOR
IC50
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |